Q2 Earnings: St Jude reports AF and neuromodulation grows, CRM lags
This article was originally published in Clinica
Executive Summary
St Jude Medical's second-quarter 2015 sales were up 6% year-over-year on a constant currency basis, driven by strong growth in atrial fibrillation, neuromodulation and vascular products, the company reported July 22.